Sitemap > News > Psychiatric, Addictive & Sleep Disorders
Displaying 1 - 50 of 190 results
- ABILIFY (aripiprazole) Supplemental New Drug Application For Pediatric Patients With Schizophrenia Accepted For Priority Review By The U.S. Food And Drug Administration
- Labopharm Initiates Phase III Clinical Study for Once-Daily Formulation of Trazodone
- NovaDel Announces Positive Data from Two Studies Comparing Zolpidem Oral Spray to Ambien(R) Tablets
- EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3 Clinical Trial
- DEPOMED INITIATES DOSING OF PATIENTS IN PHASE 2 TRIAL FOR GABAPENTIN GR FOR THE TREATMENT OF MENOPAUSAL HOT FLASHES
- Cephalon Receives FDA Approval of NUVIGIL(TM) for the Treatment of Excessive Sleepiness Associated with Three Disorders
- Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia
- Shire Receives Approvable Letter from FDA for INTUNIV™ (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD
- FDA Issues Approvable Letter for RISPERDAL
- Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
- ACADIA Pharmaceuticals Initiates Phase IIb Clinical Trial with ACP-104 in Patients with Schizophrenia
- Catalyst Pharmaceutical Partners, Inc. Initiates U.S. Phase II Clinical Trial of CPP-109 in Patients With Cocaine Dependence
- ABILIFY® (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder
- CHMP approves labelling update of Acomplia® in Europe and confirms the positive benefit-risk profile of the product except in patients suffering from ongoing major depression
- Biovail Provides Update on BVF-033
- Targacept Presents Data from TRIDMAC Trial Showing Positive Effects of Mecamylamine as Augmentation Treatment for Depressed Patients
- BioLineRx Initiates Phase II Trial of BL-1020, a First in Class GABA-Enhanced Antipsychotic for the Treatment of Schizophrenia
- Sepracor Submits LUNIVIA(R) (LUNESTA(R) in U.S.) Marketing Authorization Application (MAA) for Europe
- Valeant Pharmaceuticals Announces Full Enrollment of First Retigabine Phase 3 Epilepsy Study
- Jazz Pharmaceuticals, Inc. Announces Submission of Complete Responses to FDA Approvable Letters for Luvox CR and Luvox
- Allon and TURNS expand collaboration for Phase II schizophrenia trial
- Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc. Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
- DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
- Neurocrine Announces PDUFA Action Date of December 12, 2007 for Indiplon Capsules
- New Data Suggest Cymbalta® Reduced Pain in Fibromyalgia Patients With and Without Depression
- FDA Approves RISPERDAL® to Treat Adolescents With Schizophrenia and Children and Adolescents With Bipolar Mania
- Targacept Announces Initiation of Phase IIb Development of AZD3480 (TC-1734) for Cognitive Deficits in Schizophrenia
- Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
- Shire Undertakes Voluntary Market Withdrawal of a Limited Portion of Daytrana Product
- OVATION FURTHER ADVANCES DEVELOPMENT PIPELINE WITH NEW PHASE III EPILEPSY STUDY
- Clinical Data Announces Positive Results from Phase III Pivotal Trial of Vilazodone for Depression
- Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia with EVT 201
- Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
- Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia with EVT 201
- TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, A Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
- Allon commences Phase II schizophrenia trial and updates clinical progress
- Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
- Depomed Completes Patient Enrollment in Phase 2 Trial for Gabapentin GR for the Treatment of Menopausal Hot Flashes
- Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
- Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
- Vanda Pharmaceuticals Submits Iloperidone New Drug Application
- Lu AA21004 shows highly significant results in clinical phase II trial
- Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
- Topline Findings from Comparative Analysis of INVEGA™ and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
- NOVEN ANNOUNCES RESULTS OF PHASE 3 CLINICAL STUDY OF ONCE-DAILY LITHIUM PRODUCT
- INVEGA™ significantly reduced symptoms of schizophrenia compared to SEROQUEL® in acutely ill, hospitalized patients
- Evotec Reports Positive Top-Line Results in Phase II Study with EVT 201 in Elderly Insomniacs with Daytime Sleepiness
- Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
- FDA ISSUES APPROVABLE LETTER FOR STAVZOR™ DELAYED RELEASE VALPROIC ACID CAPSULES
- Results of VYVANSE™ (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting